Clinical Trial to Evaluate the Efficacy and Safety of MegaCarti^® in Knee Cartilage Defects

Osteoarthritis, Knee Clinical Trial

Official title:

A Clinical Trial to Evaluate the Efficacy and Safety of Cartilage Regeneration in the Use of MegaCarti^® in Patients With Knee Joint Cartilage Injury: Multicenter, Independent Evaluator-subject Blinded, Microfracture-comparative, Randomized Clinical Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06249828
• Other study ID #: LNC-MECA-004
• Status: Recruiting
• Phase: N/A
• Start date: January 22, 2024
• Est. completion date: April 30, 2025

Study information

• Verified date: February 2024
• Source: L&C Bio
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Subjects aged 50 to 65 years with knee cartilage defects will undergo microfracture treatment for cartilage regeneration and MegaCarti^® will be applied.

Description:

The MegaCarti^® is the decellularized allogeneic cartilage and acts as a cover after bone marrow stimulation to prevent the loss of blood clots and induces cartilage regeneration by assisting in the location of stem cells derived from bone marrow.

To evaluate cartilage regeneration, the study group is compared with the microfracture group alone through MOCART evaluation at 48 weeks after treatment for cartilage regeneration. In addition, a biopsy is performed to evaluate the formation of hyaline cartilage and the area ratio of regenerated cartilage is measured.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: April 30, 2025
• Est. primary completion date: April 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years to 65 Years

Eligibility

Inclusion Criteria:

1. 50 years to 65 yaers

2. After receiving a detailed explanation of this clinical trial and fully understanding it, the subject or legal representative voluntarily decides to participate in the clinical trial and sign the consent form

3. Subjects with localized full-thickness cartilage defects in the knee joint, International Cartilage Repair Society(ICRS) Grade III or IV

4. Subjects whose primary lesion site can be designated as one section of the knee joint, and the area can be determined as the main cause of clinical symptoms

5. knee cartilage defect size :1.5cm^2 to 10cm^2

Exclusion Criteria:

1. Patients who have autoimmune diseases (Ex. Rheumatoid arthritis)

2. When screening, Patients who underwent surgery related to cartilage defect treatment, such as microfracture, autologous chondrocyte therapy within the past 1 year (However, arthroscopy for diagnostic purposes is possible. Additionally, it is possible if hightibial osteotomy (HTO) has been performed in advance or is scheduled)

3. When screening, Patients who received intra-articular hyaluronic acid or steroid injections in the knee within 1 month

4. When screening, Patients who took oral steroid within 2 weeks

5. Patients who can't take MRI scan

6. BMI index : 30kg/m^2 or over

7. Patients who have gout or gout history in the knee

8. Women who are pregnant or breast-feeding, or women who have a possibility of pregnancy but do not use medically accepted methods of contraception.

9. Patients with risk factor for bleeding

10. Other than above, patients who are judged by medical investigator to be considered unsuitable for this clinical trial

Related Conditions & MeSH terms

• Osteoarthritis, Knee

Intervention

Device:
• MegaCarti^®
MegaCarti® application after microfracture through athroscopic or incision surgery

Procedure:
• Microfracture
Microfracture through athroscopic or incision surgery

Locations

Country	Name	City	State
Korea, Republic of	Ajou University Medical Center	Gyeonggi-do
Korea, Republic of	Chung-Ang University Gwangmyeong Hospital	Gyeonggi-do
Korea, Republic of	Konkuk University Medical Center	Seoul
Korea, Republic of	Yonsei University Health System, Gangnam Severance Hospital	Seoul

Sponsors (2)

Lead Sponsor	Collaborator
L&C Bio	PROMeDis

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MOCART score	The independent evaluator measure the MOCART score based on the MRI images taken at 48 weeks after surgery.; The MOCART score is an index for evaluating the degree of restoration of cartilage tissue and consists of a total of 9 items. Each item is scored from 0 to a maximum of 20 points and added up.; The MOCART score is 0 when the cartilage is in the worst condition, and 100 when it is in the best condition. In other words, when the clinical effect of tissue repair appears, it is evaluated as a score greater than 0.	From 48 weeks after surgery
Secondary	IKDC score	Subjects underwent a self-assessment of knee function using the International Knee Documentation Committee Assessment (IKDC). The outcome was presented with the post-operative change amount from the baseline.	Baseline and 12, 24, 48 weeks after surgery
Secondary	VAS	Subjects underwent a self-assessment of knee joint pain using the 100-mm Visual Analogue Scale (VAS). Use of NSAIDs and acetaminophen have to be discontinued for 24 hours, respectively, prior to the VAS evaluation. The outcome was presented with the post-operative change amount from the baseline.	Baseline and 12, 24, 48 weeks after surgery
Secondary	KOOS	Subjects underwent a self-assessment of knee joint pain using the Knee Injury and Osteoarthritis Outcome score (KOOS) survey. The outcome was presented with the post-operative change amount from the baseline.	Baseline and 12, 24, 48 weeks after surgery
Secondary	ICRS-CRA score	Investigator uses the International Cartilage Repair Society (ICRS) - cartilage repair assessment grading (CRA) system to evaluate the degree of cartilage regeneration.	From 48 weeks after surgery
Secondary	OAS	Investigator uses the Oswestry Arthroscopic Score (OAS) system to evaluate the degree of cartilage regeneration.	From 48 weeks after surgery
Secondary	Cartilage Coverage Ratio	Using arthroscopy, the investigator calculates the area of repaired cartilage that is greater than 75% defect depth.	From 48 weeks after surgery
Secondary	Histological Evaluation	Cartilage tissue is collected from the center of the repaired knee cartilage using a needle punch. After the collected tissue is stained, an independent evaluator evaluates it using the ICRS-II Parameters evaluation sheet.	From 48 weeks after surgery